Worked Renal Dose Adjustment From a Clearance Model

From a Clearance Estimate to a Regimen

A renal dose recommendation is a calculation that connects a model-based clearance estimate to a regimen with a stated exposure objective. The reference regimen provides a benchmark; the clearance model estimates how the patient’s drug clearance differs from that benchmark at the specified kidney function. The calculation can then adjust the dose, the interval, or both. It is not enough to calculate a new dose: the units, exposure target, model assumptions, and practical rounding all need to be made explicit.

The worked calculations here target the same average steady-state exposure per unit time as the reference regimen. They assume linear pharmacokinetics over the relevant dose range. For an oral regimen, they also assume that bioavailability is unchanged between the reference and patient. These assumptions make the arithmetic transparent, but they do not guarantee that peak and trough concentrations will match.

Definition: Let $D$ be dose amount, $\tau$ the dosing interval, $CL$ systemic clearance, and $F$ the fraction of a dose reaching systemic circulation. Under linear pharmacokinetics at steady state, the average concentration over a dosing interval is $$ C_{\mathrm{avg,ss}}=\frac{F D}{CL\,\tau}. $$ A regimen matches the reference average exposure when its value of $F D/(CL\,\tau)$ equals the corresponding value for the reference regimen.

If bioavailability is the same for the reference and patient, it cancels from the comparison. Write $D_{\mathrm{ref}}$, $\tau_{\mathrm{ref}}$, and $CL_{\mathrm{ref}}$ for the reference regimen and its clearance, and $D_{\mathrm{pat}}$, $\tau_{\mathrm{pat}}$, and $CL_{\mathrm{pat}}$ for the patient. Matching average exposure requires

\frac{D_{\mathrm{pat}}}{\tau_{\mathrm{pat}}} = \frac{D_{\mathrm{ref}}}{\tau_{\mathrm{ref}}} \frac{CL_{\mathrm{pat}}}{CL_{\mathrm{ref}}}.

This is a dose-rate relationship: the patient’s dose per unit time is scaled by the ratio of patient to reference clearance. If the interval is held fixed, the dose scales with clearance. If the dose is held fixed, the interval changes inversely with clearance. Those are alternative ways to match average exposure, not generally interchangeable ways to match every feature of the concentration-time profile.

Using the Clearance Model

The model must be specified before calculating a regimen. In the examples, kidney function $G$ is an already selected estimate in the units specified by the model. A simple model might be $CL(G)=CL_{\mathrm{NR}}+CL_{\mathrm{R,ref}}(G/G_{\mathrm{ref}})$, where $CL_{\mathrm{NR}}$ is the nonrenal clearance component and $CL_{\mathrm{R,ref}}$ is the renal component at reference kidney function $G_{\mathrm{ref}}$. A model may instead use a nonlinear function of $G$; the patient clearance is obtained by substituting the patient’s estimate into that stated function.

For a valid comparison, $CL_{\mathrm{ref}}$ must come from the same model evaluated at the kidney function associated with the reference regimen, or from a defensible reference clearance estimate on the same basis. Do not divide patient clearance by a reference value drawn from an incompatible model or population. Clearance units must also agree: for example, both clearances in L/h.

Result: Once the model gives $CL_{\mathrm{pat}}$ and $CL_{\mathrm{ref}}$, matching average exposure can be expressed in either of two common forms: $$ D_{\mathrm{pat}} = D_{\mathrm{ref}} \frac{\tau_{\mathrm{pat}}}{\tau_{\mathrm{ref}}} \frac{CL_{\mathrm{pat}}}{CL_{\mathrm{ref}}}, \qquad \tau_{\mathrm{pat}} = \tau_{\mathrm{ref}} \frac{D_{\mathrm{pat}}}{D_{\mathrm{ref}}} \frac{CL_{\mathrm{ref}}}{CL_{\mathrm{pat}}}. $$ The first calculates dose for a chosen interval; the second calculates interval for a chosen dose.

Worked Dose and Interval Calculations

Worked Example: Scaling the Dose at a Fixed Interval

Hypothetical data. Suppose clearance follows $CL(G)=1.2+3.6(G/100)$ L/h, where $G$ is in the model’s kidney-function units. A reference patient has $G=100$, receives 500 mg every 24 hours, and the target patient has $G=60$. Find a dose every 24 hours that matches reference average exposure.

First calculate both clearances from the same model: $$ CL_{\mathrm{ref}}=1.2+3.6(100/100)=4.80\ \mathrm{L/h}, \qquad CL_{\mathrm{pat}}=1.2+3.6(60/100)=3.36\ \mathrm{L/h}. $$

Because the interval stays at 24 hours, the dose is scaled by the clearance ratio: $$ D_{\mathrm{pat}} =500\ \mathrm{mg}\times\frac{3.36\ \mathrm{L/h}}{4.80\ \mathrm{L/h}} =350\ \mathrm{mg}. $$

Thus, 350 mg every 24 hours has the same modeled average steady-state exposure as 500 mg every 24 hours at the reference clearance. The units of clearance cancel in the ratio, leaving dose units. This result assumes linear pharmacokinetics, comparable bioavailability, and an appropriate clearance model for both individuals.

Worked Example: Using a Nonlinear Clearance Model

Hypothetical data. Suppose $CL(G)=0.9+3.9(G/100)^{0.75}$ L/h. The reference regimen is 500 mg every 24 hours at $G=100$. For a patient with $G=40$, calculate both a dose for a 24-hour interval and an interval for a 500-mg dose.

The model gives $CL_{\mathrm{ref}}=0.9+3.9=4.80$ L/h. For the patient, $$ (40/100)^{0.75}=0.5030, \qquad CL_{\mathrm{pat}}=0.9+3.9(0.5030)=2.862\ \mathrm{L/h}. $$

At a fixed 24-hour interval, the exposure-matched dose is $$ D_{\mathrm{pat}} =500\ \mathrm{mg}\times\frac{2.8616\ \mathrm{L/h}}{4.80\ \mathrm{L/h}} =298.1\ \mathrm{mg\ every\ 24\ hours}. $$

If the dose is instead held at 500 mg, solve for the interval: $$ \tau_{\mathrm{pat}} =24\ \mathrm{h}\times\frac{4.80\ \mathrm{L/h}}{2.8616\ \mathrm{L/h}} =40.26\ \mathrm{h}. $$

Both calculations target the same average exposure under the model, but they imply different concentration-time profiles. A real regimen may not allow a 40.26-hour interval or a 298.1-mg dose; those practical choices require a separate assessment rather than silently rounding the mathematical result.

Rounding and Checking the Result

Worked Example: Rounding to an Available Dose

Hypothetical data. A reference regimen is 500 mg every 24 hours at $CL_{\mathrm{ref}}=4.80$ L/h. The clearance model gives $CL_{\mathrm{pat}}=3.3411$ L/h. Suppose an available dose strength permits a 350-mg regimen every 24 hours. Calculate the unrounded matched dose and check the exposure effect of using 350 mg.

For a fixed interval, $$ D_{\mathrm{pat}} =500\ \mathrm{mg}\times\frac{3.3411\ \mathrm{L/h}}{4.80\ \mathrm{L/h}} =\frac{1670.55}{4.80}\ \mathrm{mg} =348.03125\ \mathrm{mg} \approx 348.0\ \mathrm{mg}. $$

The 350-mg option is close to the calculated dose. Its average exposure relative to the modeled target is $$ \frac{C_{\mathrm{avg,pat}}}{C_{\mathrm{avg,ref}}} = \frac{350/3.3411}{500/4.80} = \frac{350\times4.80}{500\times3.3411} = 1.0057. $$

Under the stated assumptions, 350 mg every 24 hours gives an average exposure about 0.57% above the target. This is an arithmetic comparison, not a clinical judgment that the rounded regimen is appropriate. Dose availability, formulation, therapeutic window, and other patient factors still matter.

A short derivation clarifies why the dose-rate formula uses clearance. Over one steady-state dosing interval, the amount of drug entering systemic circulation is $F D$. Under linear, time-invariant pharmacokinetics, the area under the concentration-time curve over that interval is $F D/CL$. Dividing by the interval gives average concentration:

\frac{\mathrm{AUC}_{\tau,\mathrm{ss}}}{\tau} = \frac{F D}{CL\,\tau}.

Equating this quantity for patient and reference, then cancelling equal $F$, yields the dose-rate relationship. The derivation relies on linear pharmacokinetics and steady state; it does not establish that matching average concentration also matches peak concentration, trough concentration, or a particular toxicity or efficacy endpoint.

Assumptions, Diagnostics, and Alternatives

Before interpreting a calculated regimen, check the conditions that support it. The model should apply to the selected kidney-function measure and patient context; its output should be a plausible positive clearance in the correct units. The reference clearance should correspond to the reference regimen. The drug should behave approximately linearly over the doses being compared, and the relevant clearance should not change substantially over the dosing period. For oral treatment, equal bioavailability is needed for the simple ratio; if $F$ differs, it must be included explicitly in the exposure comparison.

The calculation is also conditional on the chosen exposure goal. Matching average exposure is not the same as matching a concentration threshold or a full concentration-time profile. For instance, extending the interval while keeping the dose fixed can preserve average exposure while allowing a lower trough and a higher peak than a smaller dose at a shorter interval. A model-based recommendation therefore needs to be interpreted against the therapeutic objective and, where relevant, concentration monitoring.

Useful diagnostic checks include verifying that impaired clearance produces a lower dose rate when kidney function reduces modeled clearance, checking that calculated intervals have units of time, and independently recomputing the exposure ratio after rounding. A negative clearance, a large discontinuity inconsistent with the stated model, or a result that changes implausibly after a small change in the input should prompt a review of the model, units, and input rather than mechanical use of the output.

The main alternatives are different ways to express or refine the same dosing problem. A fixed-interval dose adjustment is often easier to implement and maintains the schedule, but may require a dose strength that is unavailable. Interval extension can retain a familiar dose amount, but changes the timing and potentially the trough. Adjusting both dose and interval is possible when the constraints of the treatment permit it. More detailed individualization can use the full pharmacokinetic model, an exposure target such as a specified AUC or concentration, and patient-specific observations; this is beyond the simple average-exposure calculation shown here.

Common pitfall: Do not multiply the reference dose by $CL_{\mathrm{ref}}/CL_{\mathrm{pat}}$ when holding the interval fixed. That reverses the ratio: lower patient clearance should lead to a lower dose rate for the same average exposure. The correct fixed-interval relation is $D_{\mathrm{pat}}=D_{\mathrm{ref}}(CL_{\mathrm{pat}}/CL_{\mathrm{ref}})$. Also avoid treating the exact model result as a ready-to-use prescription; the calculation does not account automatically for dosage-form constraints, clinical targets, or model uncertainty.

A clearance-based renal adjustment is best viewed as a transparent bridge from a model to a candidate regimen. Its strength is that the exposure-matching calculation is explicit and auditable. Its limitation is equally important: the result is only as suitable as the clearance model, exposure objective, and assumptions used to obtain it.

Check Your Understanding

Use the dose-rate relationship and state the key assumption behind each calculation.

A reference regimen is 400 mg every 12 hours at $CL_{\mathrm{ref}}=6.0$ L/h. Patient clearance is 3.0 L/h. What dose every 12 hours matches average exposure?
Using the same reference regimen and clearances, what interval for a 400-mg dose matches average exposure?
Why can a fixed dose with an extended interval match average exposure but not necessarily the reference trough concentration?
A calculated dose is 240 mg, but only 200-mg and 300-mg strengths are available. Does the clearance equation alone determine which strength should be used? Explain.

Solutions. (1) $400\times(3.0/6.0)=200$ mg every 12 hours, assuming linear pharmacokinetics and equal bioavailability. (2) $\tau_{\mathrm{pat}}=12\times(400/400)\times(6.0/3.0)=24$ hours. (3) Average exposure is an interval average; changing the interval changes the time course, so the concentration at the end of the interval need not be preserved. (4) No. The model gives an exposure-matched mathematical dose, but choosing between available strengths requires considering clinical targets, formulation, and the consequences of rounding.